These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 21134045)

  • 1. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
    Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
    Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IncobotulinumtoxinA in esthetics.
    Kerscher M; Yutskovskaya Y; Flynn TC
    J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.
    Prager W; Wissmüller E; Kollhorst B; Williams S; Zschocke I
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2155-60. PubMed ID: 21134046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
    Prager W; Bee EK; Havermann I; Zschocke I
    Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
    Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
    Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.
    Brandt F; O'Connell C; Cazzaniga A; Waugh JM
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2111-8. PubMed ID: 21134043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative evaluation of the onset and longevity of the action of incobotulinumtoxinA by skin displacement analysis in the treatment of glabellar frown lines.
    Proebstle TM; Chung G; Weissberg R; Pavicic T
    J Drugs Dermatol; 2014 Sep; 13(9):1067-72. PubMed ID: 25226007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
    Brandt F; Swanson N; Baumann L; Huber B
    Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A.
    Ghosn S; Uthman I; Dahdah M; Kibbi AG; Rubeiz N
    J Am Acad Dermatol; 2010 Dec; 63(6):1036-41. PubMed ID: 20933299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
    Shome D; Kapoor R; Khare S
    J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
    Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
    Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the spread of three botulinum toxin type A preparations.
    Kerscher M; Roll S; Becker A; Wigger-Alberti W
    Arch Dermatol Res; 2012 Mar; 304(2):155-61. PubMed ID: 22002325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem.
    Dayan SH; Arkins JP; Patel AB; Gal TJ
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2088-97. PubMed ID: 21070456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.